Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide

OBJECTIVE: The aim was to assess the real-world healthcare resource use and direct medical costs for metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone or enzalutamide, in whom chemotherapy is not yet indicated (pre-chemotherapy) or who had previously received...

Descripción completa

Detalles Bibliográficos
Autores principales: Rana, Dikshyanta, Geue, Claudia, Baillie, Kelly, Pan, Jiafeng, Mueller, Tanja, Laskey, Jennifer, Bennie, Marion, Clarke, Julie, Jones, Robert J., Brown, Ailsa, Wu, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864032/
https://www.ncbi.nlm.nih.gov/pubmed/34761368
http://dx.doi.org/10.1007/s41669-021-00307-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864032/
https://www.ncbi.nlm.nih.gov/pubmed/34761368
http://dx.doi.org/10.1007/s41669-021-00307-1

Ejemplares similares